1. Home
  2. DKI vs PHGE Comparison

DKI vs PHGE Comparison

Compare DKI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKI

DarkIris Inc. Class A Ordinary Shares

N/A

Current Price

$0.43

Market Cap

8.7M

Sector

N/A

ML Signal

N/A

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

N/A

Current Price

$7.35

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DKI
PHGE
Founded
2018
2015
Country
Hong Kong
United States
Employees
N/A
57
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7M
9.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DKI
PHGE
Price
$0.43
$7.35
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$26.00
AVG Volume (30 Days)
493.4K
87.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.25
52 Week High
$11.80
$8.50

Technical Indicators

Market Signals
Indicator
DKI
PHGE
Relative Strength Index (RSI) 47.67 64.09
Support Level $0.38 $0.41
Resistance Level $0.47 $8.50
Average True Range (ATR) 0.03 0.77
MACD -0.00 0.21
Stochastic Oscillator 47.37 92.57

Price Performance

Historical Comparison
DKI
PHGE

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: